Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 12/20 | 0.56 |
| ▸ | MTHFD1 | P11586 | 1/20 | 0.55 |
| ▸ | MTHFD2 | P13995 | 1/20 | 0.55 |
| ▸ | FOLR2 | P14207 | 1/20 | 0.44 |
| ▸ | FOLR1 | P15328 | 1/20 | 0.44 |
| ▸ | GART | P22102 | 1/20 | 0.44 |
| ▸ | SLC19A1 | P41440 | 1/20 | 0.44 |
| ▸ | SLC46A1 | Q96NT5 | 1/20 | 0.44 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | DHFR | P00374 | 1/20 | 0.39 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.38 |
| ▸ | RORC | P51449 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23005243 | 1.00 | FPR2 (0.56) | FPR2MTHFD1MTHFD2FOLR2FOLR1 | |
| SCHEMBL21515091 | 0.83 | KDM4E (0.47) | FPR2MTHFD1MTHFD2KDM4EHPGD | |
| SCHEMBL23005176 | 0.81 | FPR2 (0.63) | FPR2MTHFD1MTHFD2FOLR2FOLR1 | |
| SCHEMBL23005175 | 0.81 | FPR2 (0.63) | FPR2MTHFD1MTHFD2FOLR2FOLR1 | |
| SCHEMBL23005129 | 0.78 | FPR2 (0.50) | FPR2MTHFD1MTHFD2FOLR2FOLR1 | |
| SCHEMBL23005128 | 0.78 | FPR2 (0.50) | FPR2MTHFD1MTHFD2FOLR2FOLR1 | |
| SCHEMBL17633200 | 0.78 | SYK (0.43) | RORC | |
| SCHEMBL18551660 | 0.76 | FOLR2 (0.55) | FPR2MTHFD1MTHFD2FOLR2FOLR1 | |
| SCHEMBL23005214 | 0.76 | FPR2 (0.57) | FPR2MTHFD1MTHFD2FOLR2FOLR1 | |
| SCHEMBL23005217 | 0.76 | FPR2 (0.57) | FPR2MTHFD1MTHFD2FOLR2FOLR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3781554-B1 | 2,6-DIAMINO-3,4-DIHYDROPYRIMIDIN-4-ONE DERIVATIVES AND USE THEREOF IN THERAPY | THOMAS HELLEDAYS STIFTELSE FOER MEDICINSK FORSKNING (SE) | 2023-06-28 | — | — | EP | disclosed |
| US-20230110478-A1 | 2,6-DIAMINO-3,4-DIHYDROPYRIMIDIN-4-ONE DERIVATIVES AND USE THEREOF IN THERAPY | THOMAS HELLEDAYS STIFTELSE FÖR MEDICINSK FORSKNING (SE) | 2023-04-13 | — | — | US | disclosed |
| US-20210052587-A1 | 2,6-DIAMINO-3,4-DIHYDROPYRIMIDIN-4-ONE DERIVATIVES AND USE THEREOF IN THERAPY | MEDICINSK FORSKNING (SE) | 2021-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230110478-A1 | 2,6-DIAMINO-3,4-DIHYDROPYRIMIDIN-4-ONE DERIVATIVES AND USE THEREOF IN THERAPY | IL2, THPO, IL6 | FPR2 406/4885MTHFD1 2281/4885MTHFD2 549/4885 |
| US-20210052587-A1 | 2,6-DIAMINO-3,4-DIHYDROPYRIMIDIN-4-ONE DERIVATIVES AND USE THEREOF IN THERAPY | IL2, THPO, IL6 | FPR2 435/4885MTHFD1 2241/4885MTHFD2 478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.